Year: 2019

BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress

September 27, 2019

Bergen, Norway, 27 September 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BerGenBio to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference

September 10, 2019

Bergen, Norway, September 10 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

September 8, 2019

Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF 2019

August 19, 2019

Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo…

Read More

BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy

June 14, 2019

Two posters to be presented at the 2019 annual congress of the European Hematology Association…

Read More

BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019

June 3, 2019

  Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy n elderly AML patients…

Read More